Revelation Biosciences Extends Stock Warrants Expiration

Revelation Biosciences announced the extension of Class I Common Stock Warrants expiration to December 3, 2030, following stockholder approval. The company completed a Phase 1b clinical study for Gemini in CKD patients, showing promising inflammation treatment results. They plan to advance Gemini's development for acute kidney injury treatment, aiming for Phase 2 or 3 trials in 2026. Analysts rate REVB stock as a Buy with a $20 target, despite financial challenges and bearish technical indicators.

Revelation Biosciences Prepares Gemini for Late-Stage Acute Kidney Injury Trials

Revelation Biosciences Inc. announced the successful completion of a Phase 1b clinical study for its drug candidate Gemini in chronic kidney disease patients, showing promising results in rebalancing cellular inflammation. The company is preparing for late-stage trials targeting acute kidney injury, including scaling up manufacturing and engaging clinical partners. A key meeting with the FDA is planned to discuss regulatory pathways. Revelation Biosciences is financially strong as it aims to initiate a Phase 2 or 3 study in 2026.

Revelation Says On Track for FDA Meeting Later This Year

02:13 PM EST, 11/20/2025 (MT Newswires) -- Revelation Biosciences ( REVB ) said Thursday it is on track to hold a meeting with the US Food and Drug Administration later this year following the submission and acceptance of its end-of-phase 1 meeting package to the regulator.The meeting will establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

Revelation Biosciences Advances Gemini Toward FDA Review for Acute Kidney Injury

Revelation Biosciences Inc. has successfully submitted and received acceptance for its end-of-phase 1 meeting package to the FDA for Gemini, an investigational treatment for acute kidney injury. The company plans to hold a regulatory meeting with the FDA later this year to discuss the clinical development and regulatory approval pathway for Gemini.

Revelation Biosciences | 8-K: FY2025 Q3 Revenue: USD 0